84. サルコイドーシス ［臨床試験数：106，薬物数：161（DrugBank：74），標的遺伝子数：81，標的パスウェイ数：138］
Searched query = "Sarcoidosis"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04017936 | January 2020 | 11 November 2019 | Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis | Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis | Cardiac Sarcoidosis | Drug: Anakinra;Drug: Placebos | Virginia Commonwealth University | American Heart Association | Recruiting | 21 Years | N/A | All | 28 | Phase 2 | United States |
| 2 | NCT02523092 | December 2019 | 29 July 2019 | Use of CXCL9 as a Biomarker of Acthar Efficacy | Use of CXCL9 as a Biomarker of Acthar Efficacy | Sarcoidosis | Drug: Acthar gel | University of California, San Francisco | Mallinckrodt | Not recruiting | 18 Years | 65 Years | All | 14 | Phase 4 | United States |
| 3 | NCT03814317 | November 2019 | 22 October 2019 | Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension | An Open-Label Study of Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension and Interstitial Lung Disease (SAPPHIRE) | Sarcoidosis;Precapillary Pulmonary Hypertension;Interstitial Lung Disease | Drug: Inhaled Treprostinil | University of Florida | United Therapeutics | Not recruiting | 18 Years | 99 Years | All | 10 | Phase 2 | United States |
| 4 | NCT04064242 | October 18, 2019 | 7 October 2019 | Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis | A Subject and Investigator Blinded, Randomized, Placebo-controlled, Repeat-dose, Multicenter Study to Investigate Efficacy, Safety, and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis | Pulmonary Sarcoidosis | Drug: CMK389;Drug: Placebo | Novartis Pharmaceuticals | Not recruiting | 18 Years | 65 Years | All | 66 | Phase 2 | ||
| 5 | NCT03942211 | September 27, 2019 | 16 September 2019 | A Study in Subjects With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag | A Multicenter, Randomized, Double-blind, Group-sequential, Placebo-controlled 52-week Period Followed by a 104-week, Single-arm, Open-label Period Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag | Sarcoidosis-associated Pulmonary Hypertension | Drug: Selexipag;Drug: Placebo | Actelion | Not recruiting | 18 Years | 75 Years | All | 150 | Phase 2/Phase 3 | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT04109911 | September 25, 2019 | 14 October 2019 | Effect of Fermented Oyster Extract on Musculoskeletal Biomarkers in Relative Sarcopenia Adults | Effect of Fermented Oyster Extract on Musculoskeletal Biomarkers in Relative Sarcopenia Adults: a Randomized, Double-blinded, Placebo-controlled Trial | Muscular Sarcoidosis | Dietary Supplement: Fermented oyster extract;Dietary Supplement: Placebo | Pusan National University Yangsan Hospital | Recruiting | 50 Years | N/A | All | 54 | N/A | Korea, Republic of | |
| 7 | NCT04020380 | September 6, 2019 | 30 September 2019 | Azithromycin a Treatment for Pulmonary Sarcoidosis | A Single Arm, Open-label Exploratory Clinical Trial of Azithromycin in Pulmonary Sarcoidosis | Sarcoidosis, Pulmonary | Drug: Azithromycin 250Mg Capsule | Hull and East Yorkshire Hospitals NHS Trust | Recruiting | 18 Years | 80 Years | All | 30 | Phase 2 | United Kingdom | |
| 8 | NCT04008069 | September 3, 2019 | 16 September 2019 | Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis | A Phase II, Single-Site, Double-Blind, Placebo-Controlled Randomized Withdrawal Study Assessing the Efficacy and Safety of Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis | Sarcoidosis | Drug: Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]_#1;Drug: Placebos | Stanford University | Recruiting | 18 Years | 80 Years | All | 15 | Phase 2 | United States | |
| 9 | NCT03793439 | May 15, 2019 | 9 September 2019 | Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis | Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis | Sarcoidosis, Pulmonary;Sarcoidosis Lung;Sarcoidosis | Drug: Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial;Diagnostic Test: Spirometry;Genetic: RNA Sequencing;Diagnostic Test: Laboratory testing;Drug: Corticosteroid;Drug: Tofacitinib 5mg [Xeljanz] 1 year open-label extension | Oregon Health and Science University | Pfizer | Recruiting | 18 Years | 89 Years | All | 5 | Phase 1 | United States |
| 10 | NCT03910543 | April 11, 2019 | 20 May 2019 | Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare | Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare | Cutaneous Sarcoidosis;Granuloma Annulare | Drug: Tofacitinib 5 mg twice daily | Yale University | Pfizer | Recruiting | 18 Years | N/A | All | 15 | N/A | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT02920710 | February 1, 2019 | 26 August 2019 | ACTHAR Therapy for Central Nervous System Sarcoidosis | ACTHAR Therapy for Central Nervous System Sarcoidosis | Sarcoidosis | Drug: Repository Corticotropin Injection | The Cleveland Clinic | Mallinckrodt | Recruiting | N/A | N/A | All | 20 | Phase 4 | United States |
| 12 | NCT03824392 | January 29, 2019 | 22 October 2019 | Study of Intravenous ATYR1923 for Pulmonary Sarcoidosis | A Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of Intravenous ATYR1923 in Patients With Pulmonary Sarcoidosis | Pulmonary Sarcoidosis | Biological: ATYR1923 1.0 mg/kg or placebo;Biological: ATYR1923 3.0 mg/kg or placebo;Biological: ATYR1923 5.0 mg/kg or placebo | aTyr Pharma, Inc. | Foundation for Sarcoidosis Research | Recruiting | 18 Years | 70 Years | All | 36 | Phase 1/Phase 2 | United States |
| 13 | NCT03593759 | January 15, 2019 | 30 September 2019 | Cardiac Sarcoidosis Randomized Trial | Cardiac Sarcoidosis Multi-Center Randomized Controlled Trial | Cardiac Sarcoidosis;Sarcoidosis | Drug: Prednisone;Drug: Methotrexate | Ottawa Heart Institute Research Corporation | Canadian Institutes of Health Research (CIHR) | Recruiting | 18 Years | N/A | All | 194 | Phase 3 | United States;Canada |
| 14 | NCT03746847 | December 1, 2018 | 18 March 2019 | PET Imaging in Patients With Suspected Cardiac Sarcoidosis | Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis | Cardiac Sarcoidosis | Drug: Gallium-68 DOTATATE | University of Pennsylvania | Advanced Accelerator Applications | Not recruiting | 18 Years | N/A | All | 20 | N/A | United States |
| 15 | NCT03602976 | August 20, 2018 | 26 August 2019 | Ursodeoxycholic Acid (UDCA) for Hepatic Sarcoidosis | A Single-center, Open Label, Cross-over Study on the Effects of Ursodeoxycholic Acid (UDCA) in Patients With Hepatic Sarcoidosis | Hepatic Sarcoidosis, Elevated Alkaline Phosphatase | Drug: Ursodeoxycholic Acid | Ethan Weinberg | American Association for the Study of Liver Diseases;Exalenz Bioscience LTD. | Recruiting | 18 Years | N/A | All | 10 | Phase 2 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | NCT03549598 | July 20, 2018 | 27 August 2018 | d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis | d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis | Cardiac Sarcoidosis | Drug: 68Ga-DOTATATE PET/CT;Drug: 18FDG PET/CT scan;Drug: 13NH3 PET/CT scan | Mayo Clinic | Recruiting | 18 Years | N/A | All | 15 | Phase 4 | United States | |
| 17 | NCT03528070 | May 2018 | 11 June 2018 | A Clinical Study of Tranilast in the Treatment of Sarcoidosis | A Clinical Study of Tranilast in the Treatment of Sarcoidosis | Sarcoidosis | Drug: Tranilast | The First Affiliated Hospital with Nanjing Medical University | Not recruiting | 18 Years | N/A | All | 56 | Early Phase 1 | ||
| 18 | NCT03320070 | January 24, 2018 | 11 November 2019 | Pilot Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Pulmonary Sarcoidosis | A Phase 4, Multicenter, Randomized, Double Blind, Placebo Controlled Pilot Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Pulmonary Sarcoidosis | Sarcoidosis, Pulmonary | Drug: repository corticotropin injection;Drug: Placebo | Mallinckrodt | Recruiting | 18 Years | 90 Years | All | 100 | Phase 4 | United States | |
| 19 | NCT03324503 | December 8, 2017 | 15 July 2019 | A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis | A Multicenter, Open-Label Study to Estimate the Effect Sizes of HRCT Endpoints in Response to GLUCOCORTICOID Induction Therapy in Subjects With Pulmonary Sarcoidosis | Sarcoidosis, Pulmonary | Drug: Glucocorticoid (prednisone or prednisolone) | Celgene | Recruiting | 18 Years | 65 Years | All | 24 | N/A | United States;Netherlands;United Kingdom | |
| 20 | NCT03260556 | September 27, 2017 | 16 December 2017 | Pirfenidone for Progressive Fibrotic Sarcoidosis | Pirfenidone for Progressive Fibrotic Sarcoidosis | Sarcoidosis, Pulmonary | Drug: Pirfenidone;Drug: Placebos | University of Cincinnati | Royal Brompton & Harefield NHS Foundation Trust | Recruiting | 18 Years | 90 Years | All | 60 | Phase 4 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | NCT03103490 | August 2, 2017 | 25 February 2019 | 18F-FSPG PET/MRI or PET/CT Imaging of Cardiac Sarcoidosis or Inflammation | 18F-FSPG PET/MRI or PET/CT Imaging of Cardiac Sarcoidosis or Inflammation | Cardiac Sarcoidosis;Myocardial Inflammation | Drug: 18F-FSPG | Stanford University | GE Healthcare | Recruiting | 18 Years | N/A | All | 20 | Phase 2 | United States |
| 22 | EUCTR2016-003360-39-DE | 27/06/2017 | 28 February 2019 | Safety and efficacy of Abatacept in patients with treatment-resistant sarcoidosis | Safety and efficacy of Abatacept in patients with treatment-resistant sarcoidosis - ABASARC | Steroid-refractory Sarcoidosis MedDRA version: 20.0 Level: PT Classification code 10037430 Term: Pulmonary sarcoidosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: ORENCIA Pharmaceutical Form: Solution for injection in pre-filled syringe | Universitätsklinikum Freiburg | Authorised | Female: yes Male: yes | 30 | Phase 2 | Germany | |||
| 23 | JPRN-UMIN000025936 | 2017/06/12 | 2 April 2019 | Japanese AntibaCterial drug maNagemEnt for cardiac Sarcoidosis Trial | Cardiac sarcoidosis | combination therapy group: Prednisolone; Predonisolone start from 30mg/day and continue same dose for one month. After one month, prednisolone decrease 25mg, 20mg, 15mg, 10mg every 2-4 weeks. Finally, maintenance dose of predonisolone is 7.5mg. Antimicrobial agent; Clarithromycin start from 400mg/day for 24weeks. Doxycycline start 100mg/day for 22 weeks after 2 months of clarithromycin therapy. Prednisolone; Predonisolone start from 30mg/day and continue same dose for one month. After one month, prednisolone decrease 25mg, 20mg, 15mg, 10mg every 2-4 weeks. Finally, maintenance dose of predonisolone is 7.5mg. | National cerebral and cardiovascular center | Recruiting | 20years-old | Not applicable | Male and Female | 80 | Not selected | Japan | ||
| 24 | NCT03402308 | June 1, 2017 | 11 June 2018 | Effect of Schisandra Chinensis Extract on Musculoskeletal Biomakers in Relatively Sarcopenic Adults: a RCT | Effect of Schisandra Chinensis Extract on Musculoskeletal Biomakers in Relatively Sarcopenic Adults: a Randomized, Double-blinded, Placebo-controlled Trial | Muscular Sarcoidosis | Dietary Supplement: Schisandra chinensis extract;Dietary Supplement: Placebo | Pusan National University Yangsan Hospital | Not recruiting | 50 Years | N/A | All | 54 | N/A | Korea, Republic of | |
| 25 | JPRN-jRCTs031180301 | 01/05/2017 | 2 April 2019 | Antibacterial therapy for severe sarcoid uveitis | Study of antibacterial therapy for severe uveitis by sarcoidosis | Severe uveitis by sarcoidosis Other eyes and adnexal disease;Other eyes and adnexal disease | Ordinary steroid medication with Clarithromycin and minomycin | Hiroshi Takase | Recruiting | 20 | 80 | Both | 10 | Phase 1-2 | None | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 26 | NCT03265405 | April 1, 2017 | 1 April 2019 | Efficacy and Safety of Two Glucocorticoid Regimens in the Treatment of Sarcoidosis | Efficacy and Safety of Two Glucocorticoid Regimens in the Treatment of Sarcoidosis: a Randomized Controlled Trial | Sarcoidosis | Drug: Low dose prednisolone;Drug: Medium dose prednisolone | Postgraduate Institute of Medical Education and Research | Recruiting | 18 Years | 65 Years | All | 86 | Phase 4 | India | |
| 27 | NCT03259282 | March 7, 2017 | 11 June 2018 | Gammaglobulins Level is Predictive Factor of Evolution in Sarcoidosis | Gammaglobulins Level is Predictive Factor of Evolution in Sarcoidosis | Sarcoidosis | Biological: Analysis of gamma globulin | Rennes University Hospital | Not recruiting | N/A | N/A | All | 78 | N/A | France | |
| 28 | NCT03048097 | February 1, 2017 | 2 September 2019 | Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82 | Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82 Myocardial Perfusion Imaging for Evaluation of Cardiac Sarcoidosis | Sarcoidosis | Drug: Fluorodeoxyglucose;Drug: Rubidium;Diagnostic Test: FDG-PET/CT with Rb82 Myocardial Perfusion Imaging | Yale University | Not recruiting | 18 Years | N/A | All | 15 | Early Phase 1 | United States | |
| 29 | JPRN-jRCTs041180111 | 16/12/2016 | 10 September 2019 | Estimated by FDG PET/CT in Myocardial Sarcoidosis | Optimal Medical Therapy Estimated by FDG PET/CT in Myocardial Sarcoidosis - OMT-CS study | Cardiac sarcoidosis Cardiac sarcoidosis | After using PSL for 6 months, patients were classified by decreasing rate of TLG. If TLG is decreasing over 70%, PSL was prescribed 5mg/day for more 6 months. If TLG is decreasing under 70%, arm A: PSL was prescribed 30mg/day and diminishing PSL 5mg per month for more 6 months arm B: MTX (6mg/week) and folic acid (5mg/week) was prescribed for more 6 months | Toyoaki Murohara | Recruiting | 20age | Not applicable | Both | 50 | Phase 3 | none | |
| 30 | EUCTR2016-002160-14-NL | 22/11/2016 | 28 November 2016 | Octreotide PET/CT scan for the imaging of disease activity in neurologic and cardiac sarcoidosis. | 68Ga-DOTA-NOC PET/CT for the imaging of disease activity in neurologic and cardiac sarcoidosis. - SCAN-GO Trial | Sarcoidosis.;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: Gallium-68-DOTA-N-Octreotide Product Code: Ga-68-DOTA-NOC Pharmaceutical Form: Injection INN or Proposed INN: Ga-68-DOTA-NOC CAS Number: 1040397-47-4 Other descriptive name: DOTANOC Concentration unit: MBq megabecquerel(s) Concentration type: up to Concentration number: 160- | St. Antonius Hospital | Authorised | Female: yes Male: yes | Phase 2 | Netherlands | ||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 31 | NCT02643732 | November 2016 | 16 December 2017 | Fatigue in Sarcoidosis - Treatment With Methylphenidate | Fatigue in Sarcoidosis - A Feasibility Study Investigating the Treatment of Fatigue in Stable Sarcoidosis Patients Using Methylphenidate | Sarcoidosis;Fatigue | Drug: Methylphenidate (overencapsulated);Drug: Placebo (Over-encapsulated tablet) | University of East Anglia | Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK) | Recruiting | 18 Years | N/A | All | 30 | N/A | United Kingdom |
| 32 | EUCTR2016-001255-49-NL | 18/10/2016 | 1 October 2018 | Study of efficacy, safety and tolerability of ACZ885 (Canakinumab) in patients with pulmonary sarcoidosis | A multiple-dose, subject- and investigator-blinded, placebo-controlled, parallel design study to assess the efficacy, safety, and tolerability of ACZ885 (canakinumab) in patients with pulmonary sarcoidosis | Pulmonary sarcoidosis MedDRA version: 20.0 Level: PT Classification code 10037430 Term: Pulmonary sarcoidosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: ILARIS Product Code: ACZ885 Pharmaceutical Form: Solution for injection INN or Proposed INN: canakinumab CAS Number: 914613-48-2 Current Sponsor code: ACZ885 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use | Novartis Pharma Services AG | Authorised | Female: yes Male: yes | 38 | Phase 2 | United States;Germany;Netherlands | |||
| 33 | JPRN-UMIN000022996 | 2016/10/08 | 22 July 2019 | Optimal Medical Therapy Estimated by FDG PET/CT in Myocardial Sarcoidosis | Optimal Medical Therapy Estimated by FDG PET/CT in Myocardial Sarcoidosis - Optimal Medical Therapy in Myocardial Sarcoidosis | Myocardial sarcoidosis | mediacl therapy with methotrexate medical therapy with steroid | The Department of Cardiology, Nagoya University Graduate School of Medicine | Recruiting | 20years-old | 90years-old | Male and Female | 50 | Not selected | Japan | |
| 34 | EUCTR2016-001255-49-DE | 15/08/2016 | 28 August 2017 | Study of efficacy, safety and tolerability of ACZ885 (Canakinumab) in patients with pulmonary sarcoidosis | A multiple-dose, subject- and investigator-blinded, placebo-controlled, parallel design study to assess the efficacy, safety, and tolerability of ACZ885 (canakinumab) in patients with pulmonary sarcoidosis | Pulmonary sarcoidosis MedDRA version: 20.0 Level: PT Classification code 10037430 Term: Pulmonary sarcoidosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: ILARIS Product Code: ACZ885 Pharmaceutical Form: Solution for injection INN or Proposed INN: canakinumab CAS Number: 914613-48-2 Current Sponsor code: ACZ885 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use | Novartis Pharma Services AG | Authorised | Female: yes Male: yes | 38 | Phase 2 | United States;Netherlands;Germany | |||
| 35 | EUCTR2016-000342-60-GB | 21/06/2016 | 28 February 2019 | Fatigue and Sarcoidosis: Treatment with Methylphenidate | Fatigue in Sarcoidosis - A feasibility study investigating the treatment of fatigue in stable sarcoidosis patients using methylphenidate - Fatigue in Sarcoidosis: Treatment with Methylphenidate | Sarcoidosis-associated fatigue (Patients with stable sarcoidosis and chronic fatigue) MedDRA version: 20.1 Level: PT Classification code 10039486 Term: Sarcoidosis System Organ Class: 10021428 - Immune system disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Methylphenidate Product Name: Methylphenidate 10mg tablets Product Code: NA Pharmaceutical Form: Tablet INN or Proposed INN: Methylphenidate CAS Number: 113-45-1 Current Sponsor code: None Other descriptive name: None Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use | Norfolk and Norwich University Hospital | Not Recruiting | Female: yes Male: yes | 30 | Phase 2 | United Kingdom | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 36 | NCT02812849 | June 2016 | 16 December 2017 | Somatostatin Receptor Imaging in Cardiac Sarcoidosis | Somatostatin Receptor Imaging in Cardiac Sarcoidosis | Cardiac Sarcoidosis | Drug: Cu-64 DOTATATE | Rigshospitalet, Denmark | Recruiting | 18 Years | N/A | All | 60 | N/A | Denmark | |
| 37 | NCT02298491 | May 2016 | 26 August 2019 | CNS Sarcoidosis and Acthar Gel | Clinical Biomarkers of Disease Activity and Treatment Responses in Patients With CNS Sarcoidosis Treated With H.P. Acthar Gel | CNS Sarcoidosis | Drug: H.P. Acthar Gel | University of Maryland, Baltimore | Mallinckrodt | Not recruiting | N/A | N/A | All | 4 | Phase 4 | United States |
| 38 | NCT02824419 | May 2016 | 21 July 2016 | Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis | Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis | Pulmonary Sarcoidosis | Drug: Methionine;Drug: DOTANOC | Turku University Hospital | Recruiting | 18 Years | N/A | Both | 10 | Phase 2/Phase 3 | Finland | |
| 39 | EUCTR2015-001815-11-FI | 19/04/2016 | 2 May 2016 | PET imaging of pulmonary sarcoidosis | Imaging of active granulomas with [18F]FDG and selected inflammatory PET tracers in pulmonary sarcoidosis | Pulmonary sarcoidosis with active garnulomas in the lungs. The diagnosis is based on the clinical evidence or biopsy. MedDRA version: 18.1 Level: PT Classification code 10037430 Term: Pulmonary sarcoidosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01] | Product Name: 18F-fluorodeoxyglucose Product Code: FDG Pharmaceutical Form: Infusion INN or Proposed INN: FLUORINE (18F) FLUDEOXYGLUCOSE CAS Number: 105851-17-0 Concentration unit: MBq megabecquerel(s) Concentration type: range Concentration number: 170-185 Product Name: C11-methionine Pharmaceutical Form: Infusion INN or Proposed INN: L-methionine Other descriptive name: L-METHIONINE ([11C]METHYL) Concentration unit: MBq megabecquerel(s) Concentration type: range Concentration number: 400-440 Product Name: 68Ga-DOTANOC Pharmaceutical Form: Infusion INN or Proposed INN: DOTANOC Other descriptive name: DOTANOC Concentration unit: MBq megabecquerel(s) Concentration type: range Concentration number: 170-185 | Turku PET Centre | Authorised | Female: yes Male: yes | Finland | |||||
| 40 | NCT02725177 | March 2016 | 11 March 2019 | Ocular Sarcoidosis Open Label Trial of ACTHAR Gel | Ocular Sarcoidosis Open Label Trial of ACTHAR Gel | Ocular Sarcoidosis;Panuveitis;Anterior Uveitis | Drug: Repository Corticotropin Injection;Drug: Repository Corticotropin Injection -Treatment Extension | The Cleveland Clinic | Mallinckrodt | Recruiting | 18 Years | 99 Years | All | 20 | N/A | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 41 | NCT02546388 | October 2015 | 17 September 2018 | Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis | Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis | Sarcoidosis | Drug: Indium-111 Pentreotide | Marcelo F. Di Carli, MD, FACC | Mallinckrodt | Not recruiting | 18 Years | 90 Years | All | 17 | N/A | United States |
| 42 | NCT02497079 | July 2015 | 3 August 2015 | Diagnostic Accuracy of Polymerase Chain Reaction for Mycobacterium Tuberculosis Using EBUS-TBNA Samples | Comparison of the Diagnostic Accuracy of Nested and Real-time Polymerase Chain Reaction for Mycobacterium Tuberculosis Using EBUS-TBNA Samples in Patients With Isolated Intrathoracic Lymphadenopathy | Lymphadenopathy;Tuberculosis;Sarcoidosis | Device: Nested PCR for formalin-fixed tissues;Device: Nested PCR for fresh tissues;Device: Real-time PCR for fresh tissues | Pusan National University Hospital | Recruiting | 18 Years | N/A | Both | 100 | N/A | Korea, Republic of | |
| 43 | EUCTR2013-005333-21-NL | 30/06/2015 | 14 September 2015 | Study of efficacy, safety and tolerability of ACZ885 (Canikumab) in patients with pulmonary sarcoidosis | A multiple-dose, double-blind, placebo-controlled, parallel study to assess the efficacy, safety and tolerability of ACZ885 (Canikumab) in patients with pulmonary sarcoidosis | Pulmonary sarcoidosis MedDRA version: 17.1 Level: PT Classification code 10037430 Term: Pulmonary sarcoidosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: ILARIS Product Name: Canakinumab Product Code: ACZ885 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: Canakinumab CAS Number: 914613-48-2 Current Sponsor code: ACZ885 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use | Novartis Pharma Services AG | Not Recruiting | Female: yes Male: yes | 90 | United States;Netherlands | ||||
| 44 | EUCTR2014-002224-26-NL | 07/05/2015 | 10 July 2015 | Infliximab dosing based on blood concentrations in patients with sarcoidosis: smart dosing | A new dosing strategy of infliximab versus standard dosing in patients with severe sarcoidosis: optimization of treatment - Concentration guided dosing of infliximab in sarcoidosis | Sarcoidosis;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Remicade Product Name: Remicade Pharmaceutical Form: Powder for concentrate for solution for injection/infusion | St. Antonius Hospital | Authorised | Female: yes Male: yes | Netherlands | |||||
| 45 | NCT02625558 | April 2015 | 14 December 2015 | Riociguat for Sarcoidosis Associated Pulmonary Hypertension | A Double Blind, Placebo Controlled Trial of Oral Riociguat for Sarcoidosis Associated Pulmonary Hypertension | Sarcoidosis | Drug: Riociguat;Drug: Placebo | University of Cincinnati | Recruiting | 18 Years | N/A | Both | 60 | Phase 4 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 46 | NCT02348905 | March 2015 | 19 February 2015 | ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label Trial | ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label Trial | Sarcoidosis;Cutaneous Sarcoidosis | Drug: ACTHAR Gel 40 units twice weekly;Drug: ACTHAR Gel 80 units twice weekly. | Albany Medical College | Not recruiting | 18 Years | N/A | Both | 10 | Phase 2/Phase 3 | United States | |
| 47 | NCT02155803 | February 2015 | 19 February 2015 | ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study | ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study | Sarcoidosis;Hypercalcemia Due to Sarcoidosis | Drug: ACTHAR Gel (adrenocorticotropic hormone) | Albany Medical College | Not recruiting | 18 Years | N/A | Both | 10 | Phase 2/Phase 3 | United States | |
| 48 | NCT02246023 | January 2015 | 25 April 2016 | Fractionated Versus Target-controlled Propofol Administration in Bronchoscopy | Target-controlled Versus Manually-controlled Propofol Sedation in Flexible Bronchoscopy. A Randomized Non-inferiority Trial. | Lung Cancer;Sarcoidosis;Interstitial Pneumonia | Device: Flexible bronchoscopy in moderate sedation;Device: Oxygen saturation;Device: Blood pressure;Device: Propofol dosage;Device: Recovery time after bronchoscopy | Daniel Franzen | B. Braun Melsungen AG | Not recruiting | 18 Years | 85 Years | Both | 78 | Phase 4 | Switzerland |
| 49 | NCT02192489 | November 2014 | 10 October 2016 | A Phase 2 Study With CC-220 in Skin Sarcoidosis | A Phase 2A, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Sequential, Dose-Ascending Study Of CC-220 In Subjects With Chronic Cutaneous Sarcoidosis | Sarcoidosis | Drug: CC-220 0.3 mg Daily;Drug: CC-220 0.6mg Daily;Drug: Placebo | Celgene Corporation | Not recruiting | 18 Years | N/A | Both | 0 | Phase 2 | ||
| 50 | NCT02265874 | October 2014 | 16 December 2017 | Nicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot Study | Nicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot Study | Sarcoidosis | Drug: Habitrol;Drug: Placebo to Habitrol | Ohio State University | The Cleveland Clinic | Recruiting | 18 Years | 75 Years | All | 60 | Phase 1/Phase 2 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 51 | EUCTR2013-005376-17-NL | 20/06/2014 | 14 March 2016 | Sandostatin therapy in sarcoidosis | Sandostatin therapy in sarcoidosis - SST in SA | Sarcoidosis MedDRA version: 16.1 Level: HLGT Classification code 10003816 Term: Autoimmune disorders System Organ Class: 10021428 - Immune system disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Sandostatin LAR Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: OCTREOTIDE CAS Number: 83150-76-9 Current Sponsor code: SMS 201-995 Other descriptive name: octreotide LAR / Sandostatin LAR (LAR=long acting release) Concentration unit: mg milligram(s) Concentration type: range Concentration number: 20-30 | Erasmus Medical Center | Not Recruiting | Female: yes Male: yes | Netherlands | |||||
| 52 | NCT02188017 | June 2014 | 14 December 2015 | Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS) | ACTHAR Gel for Chronic Pulmonary Sarcoidosis (ACPS) | Sarcoidosis;Pulmonary Sarcoidosis | Drug: Acthar gel | University of Cincinnati | Mallinckrodt | Recruiting | 18 Years | 90 Years | Both | 20 | Phase 4 | United States |
| 53 | NCT01955824 | May 2014 | 19 February 2015 | A Trial on Clinical Efficacy of 1% Versus 2% Lignocaine in Cough Suppression and Pain Relief in Patients Undergoing Flexible Bronchoscopy | A RCT ON CLINICAL EFFICACY OF 1% vs. 2% LIGNOCAINE IN COUGH SUPPRESSION AND PAIN RELIEF IN PATIENTS UNDERGOING FLEXIBLE BRONCHOSCOPY | Lung Cancer;Tuberculosis;Sarcoidosis;Interstitial Lung Disease | Drug: 1% lignocaine;Drug: 2% lignocaine | Postgraduate Institute of Medical Education and Research | Not recruiting | 12 Years | 80 Years | Both | 500 | Phase 2/Phase 3 | India | |
| 54 | NCT02036970 | May 2014 | 14 January 2019 | Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT | A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension | Pulmonary Arterial Hypertension;Pulmonary Hypertension;Interstitial Lung Disease;Idiopathic Interstitial Pneumonia;Idiopathic Pulmonary Fibrosis;Sarcoidosis;Respiratory Bronchiolitis Associated Interstitial Lung Disease;Desquamative Interstitial Pneumonia;Cryptogenic Organizing Pneumonia;Acute Interstitial Pneumonitis;Idiopathic Lymphoid Interstitial Pneumonia;Idiopathic Pleuroparenchymal Fibroelastosis | Drug: Bardoxolone methyl;Drug: Placebo | Reata Pharmaceuticals, Inc. | Not recruiting | 18 Years | 75 Years | All | 166 | Phase 2 | United Kingdom;Spain;United States;Germany | |
| 55 | JPRN-UMIN000013831 | 2014/04/30 | 2 April 2019 | Effect of inhaled corticosteroid therapy in pulmonary sarcoidosis patients who manifest airflow limitation | Pulmonary sarcoidosis patients who revealed airflow limitation in peak flow tests, increased respiratory resistance in IOS, or increased WA% in HRCT. | inhaled ciclesonide (400maicrogram, twice daily, for three months) | Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan | Recruiting | 20years-old | 80years-old | Male and Female | 40 | Not selected | Japan | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 56 | NCT01210677 | April 2014 | 19 February 2015 | Cardiac Sarcoidosis Response To Steroids Trial | CArdiac Sarcoidosis Response TO steRoids (CASTOR) Trial | Cardiac Sarcoidosis;Sarcoidosis | Drug: Prednisone | Ottawa Heart Institute Research Corporation | Not recruiting | 18 Years | N/A | Both | 0 | Phase 4 | Canada | |
| 57 | NCT02024555 | March 2014 | 24 June 2019 | Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis | Investigation of the Efficacy of Antimycobacterial Therapy on Pulmonary Sarcoidosis Phase II Randomized, Double-blind, Placebo-controlled Trial | Sarcoidosis; Antimycobacterial Therapy | Drug: Levofloxacin;Drug: Ethambutol;Drug: Azithromycin;Drug: Rifampin;Drug: Placebo | Vanderbilt University | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | 18 Years | N/A | All | 97 | Phase 2 | United States |
| 58 | NCT02039687 | January 2014 | 16 December 2017 | Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis | A Double Blind, Placebo Controlled Phase 2 Dose Ranging Study of the Effects of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis | Neuropathy of Sarcoidosis | Drug: ARA 290;Other: Placebo | Araim Pharmaceuticals, Inc. | Not recruiting | 18 Years | 70 Years | All | 64 | Phase 2 | United States;Netherlands | |
| 59 | NCT02134717 | January 2014 | 16 December 2017 | Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes | An Interventional Study of the Effect of CCR5 Inhibition With Maraviroc on Immune Cells in the the Lung and in Peripheral Blood of Patients With Sarcoidosis | Sarcoidosis | Drug: all subjects will receive maraviroc 300mg orally twice a day for 6 weeks;Procedure: Bronchoscopy with bronchoalveolar lavage;Procedure: venipunctures;Procedure: Skin biopsy | Kevin F. Gibson | University of Pittsburgh | Not recruiting | 18 Years | 80 Years | All | 3 | N/A | United States |
| 60 | EUCTR2013-003016-45-NL | 11/09/2013 | 10 July 2015 | study the safety and effects of different doses of ARA 290 administered subcutaneously on the corneal nerve fiber density and symptoms of neuropathic pain in sarcoidosis patients. | A double blind, placebo controlled Phase 2 dose ranging study of the effects of ARA 290 on corneal nerve fiber density and neuropathic symptoms of patients with sarcoidosis - DOSARA | small fiber neuropathy;Therapeutic area: Body processes [G] - Biological Phenomena [G16] | Product Name: ARA 290 Product Code: ARA 290 Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: ARA 290 Current Sponsor code: ARA 290 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 1-8 Pharmaceutical form of the placebo: Powder for solution for injection/infusion Route of administration of the placebo: Subcutaneous use | Araim Pharmaceuticals | Not Recruiting | Female: yes Male: yes | 64 | Phase 2 | United States;Netherlands | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 61 | EUCTR2013-000242-18-NL | 23/05/2013 | 3 June 2013 | Low dose dexamethasone in newly diagnosed sarcoidosis | Low dose dexamethasone in newly diagnosed sarcoidosis - (DEXSAR) Trial | Patients with newly diagnosed, pulmonary sarcoidosis;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Dexamethasone 0,5mg Product Name: Dexamethasone Pharmaceutical Form: Tablet INN or Proposed INN: DEXAMETHASONE CAS Number: 50-02-2 Current Sponsor code: Tiofarma Other descriptive name: Dexamethasone Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Authorised | Female: yes Male: yes | Netherlands | ||||||
| 62 | NCT01830959 | April 2013 | 14 December 2015 | Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS) | Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS) | Sarcoidosis | Drug: Roflumilast;Drug: Placebo | University of Cincinnati | The Cleveland Clinic;University of Pittsburgh;University of Illinois at Chicago;Henry Ford Health System;Albany Medical College | Not recruiting | 18 Years | 70 Years | Both | 50 | Phase 4 | United States |
| 63 | NCT01732211 | March 2013 | 17 November 2015 | A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis | A Phase 2 Randomized, Double Blind, Placebo Controlled, Parallel Group, 20-week Safety, Tolerability, And Efficacy Study Of Pd 0360324 In Adult Subjects With Chronic Pulmonary Sarcoidosis | Pulmonary Sarcoidosis | Biological: PD 0360324;Other: Normal Saline for injection | Pfizer | Not recruiting | 21 Years | 75 Years | Both | 1 | Phase 2 | United States | |
| 64 | NCT01652417 | October 2012 | 14 March 2016 | Treatment of Renal Sarcoidosis by Methylprednisolone Bolus | Randomized, Multicentric Study Evaluating the Efficacy and the Safety of Methylprednisolone Bolus in the Treatment of Renal Sarcoidosis | Renal Sarcoidosis | Drug: methylprednisolone bolus IV 15 mg/kg/d for 3 days. | Assistance Publique - Hôpitaux de Paris | Not recruiting | 18 Years | N/A | Both | 40 | N/A | France | |
| 65 | NCT01687517 | October 2012 | 4 May 2015 | Efficacy and Safety of Influenza Vaccine During Sarcoidosis | Determination of the Efficacy and Safety of the Seasonal Influenza Vaccine Among Patients Suffering From Sarcoidosis. | Sarcoidosis;Influenza Vaccine | Drug: Seasonal influenza vaccine available for the 2012-2013 vaccine campaign | Assistance Publique - Hôpitaux de Paris | Not recruiting | 18 Years | 65 Years | Both | 190 | Phase 3 | France | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 66 | NCT01648933 | July 2012 | 22 October 2018 | Perfusion Analysis Using Rubidium in Cardiac Sarcoidosis | Perfusion Analysis Using Rubidium in Cardiac Sarcoidosis | Sarcoidosis | Radiation: Rubidium PET | Assistance Publique - Hôpitaux de Paris | Not recruiting | 18 Years | N/A | All | 53 | N/A | France | |
| 67 | ChiCTR-IOR-15005953 | 2012-01-01 | 18 April 2017 | The effects of corticosteroid treatment on asymptomatic sarcoidosis | The effects of corticosteroid treatment on asymptomatic sarcoidosis | Sarcoidosis | Corticosteroid-treated group :prednisolone ;Placebo:Placebo; | The First Affiliated Hospital, Guangzhou Medical University | Not Recruiting | 18 | 76 | Both | Corticosteroid-treated group :64;Placebo:63; | Other | ||
| 68 | EUCTR2011-003630-13-NL | 22/11/2011 | 14 July 2014 | Tracer for the imaging of disease activity in sarcoidosis in the lung | 99mTc labelled anti-TNF-alpha for the imaging of disease activity in pulmonary sarcoidosis - TISS | Pulmonary sarcoidosis MedDRA version: 17.0 Level: PT Classification code 10037430 Term: Pulmonary sarcoidosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: 99mTc-Infliximab Product Code: not applicable Pharmaceutical Form: Radiopharmaceutical precursor, solution INN or Proposed INN: not applicable CAS Number: not applicab Current Sponsor code: not applicable Other descriptive name: 99m technetium infliximab Concentration unit: MBq megabecquerel(s) Concentration type: equal Concentration number: 370 - | Sint Antonius Hospital | Authorised | Female: yes Male: yes | Netherlands | |||||
| 69 | NCT01587001 | November 2011 | 16 December 2017 | The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis | The Effect of an Oral Antioxidant, N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis | Pulmonary Sarcoidosis | Dietary Supplement: N-acetyl-cysteine;Drug: Placebo | National Jewish Health | American Thoracic Society | Not recruiting | 18 Years | 80 Years | All | 17 | N/A | United States |
| 70 | NCT01440192 | September 2011 | 12 March 2018 | Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis | A Phase 1B, Multi-Center, Open-Label, Single Dose Study to Evaluate the Safety of Intravenous Infusion of Human Placental-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis.Sarcoidosis | Stage 2 Pulmonary Sarcoidosis;Stage 3 Pulmonary Sarcoidosis | Biological: PDA001 (cenplacel-L) | Celularity Incorporated | Not recruiting | 18 Years | 75 Years | All | 4 | Phase 1 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 71 | NCT01324999 | March 2011 | 16 December 2017 | Tadalafil for Sarcoidosis Associated Pulmonary Hypertension | Tadalafil for Sarcoidosis Associated Pulmonary Hypertension | Pulmonary Hypertension | Drug: Tadalafil | University of North Carolina, Chapel Hill | Eli Lilly and Company;United Therapeutics;University of Cincinnati | Not recruiting | 18 Years | N/A | All | 12 | Phase 2/Phase 3 | United States |
| 72 | JPRN-UMIN000004267 | 2010/10/01 | 2 April 2019 | PET/CT finding of cardiac sarcoidosis | sarcoidosis | Give heparin Na before 18F-FDG PET/CT in the diagnosis of cardial sarcoidosis. | Tokushima University Hospital | Not Recruiting | Not applicable | Not applicable | Male and Female | 30 | Not selected | Japan | ||
| 73 | NCT03621553 | July 1, 2010 | 7 October 2019 | Vitamin D Homeostasis in Sarcoidosis | Vitamin D Homeostasis in Sarcoidosis | Sarcoidosis;Vitamin D Insufficiency | Drug: Ergocalciferol;Drug: Placebo;Drug: Calcium Citrate with Vitamin D2 | University of Texas Southwestern Medical Center | Recruiting | 21 Years | N/A | All | 90 | Phase 4 | United States | |
| 74 | NCT01169038 | July 2010 | 19 October 2017 | Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis | Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis | Pulmonary Sarcoidosis;Lung Function | Drug: levaquin; ethambutol; rifampin and azithromycin. | Vanderbilt University | Not recruiting | 18 Years | 75 Years | All | 15 | Phase 1 | United States | |
| 75 | JPRN-UMIN000006533 | 2010/04/01 | 2 April 2019 | Detecting sympathetic denervation and regional myocardial inflammation using 11C-hydroxyephedrine (HED) PET/CT and 18F-fluorodeoxyglucose (FDG) PET/CT and their relationship with arrhythmia in patients with cardiac involvement sarcoidosis and assessment of therapeutic effects | sarcoidosis | All patients with first diagnosis of cardiac sarcoidosis or without steroid treatment will undergo 11C HED PET/CT,18F FDG PET/CT, 15O-PET water, MIBG, 12 leads ECG, AECG , SAECG and echocardiogram (Echo) before starting corticosteroid therapy and repeat study at 4 weeks after starting corticosteroid therapy. These patients will also have reevaluation 6 to 12 month after the second evaluations. Sarcoidosis without cardiac involvement will undergo steroid treatment will also repeat the same measurements 4 weeks after the treatment. Cardiac sarcoidosis but will not have steroid treatment will also repeat the same measurements 12 months later. Sarcoidosis patients without steroid treatment will also repeat the same measurements 12 months later. Cardiac sarcoidosis with steroid treatment. Cardiac sarcoidosis without steroid treatment. arcoidosis without cardiac involvement who will have steroid treatement. Sarcoidosis without cardiac involvement who will not have steroid treatement. Normal control. | Hokkaido University Graduate School of Medicine, | Recruiting | Not applicable | Not applicable | Male and Female | 50 | Not applicable | Japan | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 76 | NCT01074554 | February 2010 | 19 October 2017 | Trial of Antimycobacterial Therapy in Sarcoidosis | Phase I/II Study of the Effects of Antibiotics on Sarcoidosis Pathogenesis | Sarcoidosis | Drug: Antibiotic Regimen;Drug: Placebo Regimen | Vanderbilt University | Not recruiting | 18 Years | N/A | All | 30 | Phase 1/Phase 2 | United States | |
| 77 | EUCTR2009-010714-30-BE | 28/09/2009 | 11 August 2014 | A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients with Sarcoidosis | A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sarcoidosis | Chronic sarcoidosis MedDRA version: 13.1 Level: PT Classification code 10039486 Term: Sarcoidosis System Organ Class: 10021428 - Immune system disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Golimumab Liquid in prefilled syringe Product Code: CNTO 148 Pharmaceutical Form: Solution for injection INN or Proposed INN: golimumab Current Sponsor code: CNTO 148 Other descriptive name: Human anti TNF-alpha monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use Product Name: ustekinumab liquid in prefilled syringe Product Code: CNTO1275 Pharmaceutical Form: Solution for injection INN or Proposed INN: ustekinumab Current Sponsor code: CNTO 1275 Other descriptive name: Human anti-IL 12/23 monoclonal antibody Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 90- Pharmaceutical form of the placebo: Solution for injection Route of administration of the placebo: Subcutaneous use | Janssen Biologics B.V. | Not Recruiting | Female: yes Male: yes | 180 | Phase 2 | France;United States;Belgium;Denmark;Germany;Norway;Netherlands;Italy;United Kingdom | |||
| 78 | NCT00918554 | September 2009 | 19 February 2015 | Efficacy Study of Methotrexate to Treat Sarcoid-associated Uveitis | Corticosteroid Sparing Effect of Methotrexate in Patients With Sarcoid- Associated Uveitis: A Double Blind, Randomized, Placebo Controlled-study -UVEXATE | Sarcoid-associated Uveitis;Ocular Sarcoidosis;Macular Edema | Drug: Methotrexate;Drug: Placebo | Assistance Publique - Hôpitaux de Paris | Not recruiting | 18 Years | N/A | Both | 7 | Phase 4 | France | |
| 79 | NCT00855205 | July 2009 | 19 February 2015 | Rituximab for Pulmonary Sarcoidosis | Rituximab as a Novel Therapy in Refractory Sarcoidosis: A Prospective Open- | Sarcoidosis | Drug: Rituximab | University of Cincinnati | University of Chicago | Not recruiting | 18 Years | N/A | Both | 10 | Phase 2 | United States |
| 80 | NCT00731757 | May 2009 | 19 February 2015 | Efficacy Study of Humira in the Treatment of Cutaneous Sarcoidosis | A Phase II, Multi-Center, Open Label Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis | Sarcoidosis;Cutaneous Sarcoidosis | Drug: Humira | Wright State University | Stanford University | Not recruiting | 18 Years | N/A | Both | 20 | Phase 2 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 81 | NCT02200146 | March 2009 | 19 February 2015 | Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS). | Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS). A Multicenter, Prospective, Controlled, Randomized Trial. | Pulmonary Sarcoidosis | Drug: Prednisone;Drug: Hydroxychloroquine + Prednisone | University of Milano Bicocca | Agenzia Italiana del Farmaco | Not recruiting | 18 Years | 70 Years | Both | 94 | Phase 3 | Italy |
| 82 | NCT01245036 | January 2009 | 19 February 2015 | Efficacy of Antituberculous Therapy in Management of Sarcoidosis | Rifampicin and Isoniazid Along With Prednisolone Compared to Prednisolone Alone in Treatment of Sarcoidosis: a Pilot Randomized Controlled Trial | Sarcoidosis;Tuberculosis | Drug: Antituberculous therapy along with steroids | Postgraduate Institute of Medical Education and Research | Not recruiting | 15 Years | 75 Years | Both | 100 | N/A | India | |
| 83 | NCT00828828 | December 2008 | 19 February 2015 | Antibody Response to Influenza Vaccine in Patients With Sarcoidosis | Controlled Trial of Serologic Efficacy of Influenza Vaccine in Patients With Sarcoidosis | Pulmonary Sarcoidosis | Biological: Influenza Vaccine | Shahid Beheshti Medical University | Not recruiting | 20 Years | 60 Years | Both | 49 | Phase 3 | Iran, Islamic Republic of | |
| 84 | NCT00794274 | November 2008 | 19 February 2015 | The Efficacy and Safety of CC-10004 in Chronic Cutaneous Sarcoidosis | The Efficacy and Safety of CC-10004 in Chronic Cutaneous Sarcoidosis | Sarcoidosis;Cutaneous Sarcoidosis | Drug: CC-100004 | University of Cincinnati | Celgene Corporation;Medical University of South Carolina | Not recruiting | 18 Years | 80 Years | Both | 15 | Phase 2/Phase 3 | United States |
| 85 | NCT00851929 | November 2008 | 20 August 2018 | Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension | Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension | Sarcoidosis;Pulmonary Hypertension | Drug: Ambrisentan | Medical University of South Carolina | Gilead Sciences | Not recruiting | 18 Years | 99 Years | All | 16 | Phase 2/Phase 3 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 86 | NCT00739960 | August 2008 | 19 February 2015 | Safety Study of Abatacept to Treat Refractory Sarcoidosis | Sarcoidosis, Trial of Abatacept in Refractory Disease (STAR). A Prospective Open-Label Trial of Abatacept in Progressive Sarcoidosis | Sarcoidosis | Drug: Abatacept | University of Chicago | Bristol-Myers Squibb | Not recruiting | 18 Years | N/A | Both | 1 | Phase 2 | United States |
| 87 | NCT00701207 | July 2008 | 19 February 2015 | Study of Nicotine Patches in Patients With Sarcoidosis | Modulation of Pulmonary Sarcoidosis by Nicotinic Acetylcholine Receptors | Pulmonary Sarcoidosis | Drug: nicotine patch | Elliott Crouser MD | American Thoracic Society | Not recruiting | 18 Years | N/A | Both | 64 | Phase 4 | United States |
| 88 | EUCTR2008-001340-39-IT | 30/06/2008 | 19 March 2012 | Hydroxychloroquine as Steroid-Sparing Agent in pulmonary Sarcoidosis (HySSAS). A multicenter, prospectic, controlled, randomized trial. - HySSAS | Hydroxychloroquine as Steroid-Sparing Agent in pulmonary Sarcoidosis (HySSAS). A multicenter, prospectic, controlled, randomized trial. - HySSAS | Pulmonary Sarcoidosis | Trade Name: PLAQUENIL*25CPR RIV 200MG Pharmaceutical Form: Coated tablet INN or Proposed INN: Hydroxychloroquine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Trade Name: DELTACORTENE*10CPR 25MG Pharmaceutical Form: Tablet INN or Proposed INN: Prednisone Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA | Authorised | Female: yes Male: yes | Italy | |||||
| 89 | EUCTR2007-005117-18-AT | 03/04/2008 | 19 March 2012 | Safety and efficacy study of bosentan in progressive pulmonary sarcoidosis - BOPSAC | Safety and efficacy study of bosentan in progressive pulmonary sarcoidosis - BOPSAC | Progressive pulmonary sarcoidosis MedDRA version: 9.1 Level: PT Classification code 10037430 Term: Pulmonary sarcoidosis | Trade Name: Tracleer Product Name: Bosentan Pharmaceutical Form: Coated tablet Pharmaceutical form of the placebo: Coated tablet Route of administration of the placebo: Oral use | Medical University of Vienna, Department of Clinical Pharmacology | Not Recruiting | Female: yes Male: yes | Austria | |||||
| 90 | NCT00581607 | April 2008 | 19 February 2015 | Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension | Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension | Sarcoidosis;Pulmonary Arterial Hypertension | Drug: Bosentan;Drug: Placebo | University of Cincinnati | Actelion | Not recruiting | 18 Years | N/A | Both | 43 | Phase 2/Phase 3 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 91 | NCT00555347 | October 2007 | 8 June 2015 | Use of Armodafinil for Fatigue in Sarcoidosis | Use of Armodafinil (R-modafinil) for Fatigue in Sarcoidosis | Sarcoidosis;Fatigue;Sleepiness | Drug: Armodafinil;Drug: Placebo | University of Cincinnati | Cephalon | Not recruiting | 18 Years | N/A | Both | 20 | Phase 2/Phase 3 | United States |
| 92 | NCT00690911 | August 2007 | 16 December 2017 | Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis | A Phase II, Multi-Center, Open Label Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis (HUM 04-36) | Sarcoidosis | Drug: adalimumab | Wake Forest University | Not recruiting | 18 Years | N/A | All | 0 | Phase 2 | United States | |
| 93 | EUCTR2006-005361-19-GB | 09/03/2007 | 19 March 2012 | Evaluation of the efficacy of the dual endothelin 1 receptor antagonist Bosentan in the treatment of Pulmonary Hypertension secondary to Chronic Obstructive Pulmonary Disease and in the treatment of Pulmonary Hypertension secondary to sarcoidosis | Evaluation of the efficacy of the dual endothelin 1 receptor antagonist Bosentan in the treatment of Pulmonary Hypertension secondary to Chronic Obstructive Pulmonary Disease and in the treatment of Pulmonary Hypertension secondary to sarcoidosis | Pulmonary Hypertension secondary to Chronic Obstructive Pulmonary Disease and secondary to Sarcoid Patients devolop pulmonary hypertension for various reasons, two common causes are Chronic Obstructive Pulmonary disease and Sarcoid. Once developed it may go on to cause right heart failure and severe breathlessness and eventually death. We believe that the use of bosentan may lower the pulmonary hypertension and improve symptoms. MedDRA version: 8.1 Level: LLT Classification code 10037400 Term: Pulmonary hypertension | Trade Name: Tracleer Product Name: tracleer Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Bosentan monohydrate CAS Number: 147536978 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 62.5mg-125mg | St Georges Hospital | Authorised | Female: yes Male: yes | 45 | United Kingdom | ||||
| 94 | NCT00403650 | November 2006 | 19 February 2015 | Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension | Inhaled Iloprost for Sarcoidosis Associated Pulmonary Hypertension | Sarcoidosis;Pulmonary Arterial Hypertension | Drug: Iloprost | University of Cincinnati | Not recruiting | 18 Years | 90 Years | Both | 20 | Phase 4 | United States | |
| 95 | NCT00274352 | September 2006 | 19 February 2015 | A Study of Adalimumab to Treat Sarcoidosis of the Skin | A Double-Blind, Randomized, Placebo-Controlled Study of Adalimumab in the Treatment of Cutaneous Sarcoidosis | Sarcoidosis | Drug: adalimumab | Pariser, Robert J., M.D. | Abbott;Virginia Clinical Research, Inc. | Not recruiting | 18 Years | 89 Years | Both | 16 | Phase 2 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 96 | NCT00361387 | June 2006 | 19 February 2015 | Use of Focalin for Fatigue in Sarcoidosis | Randomized, Double-Blind, Placebo-Controlled Study of Dexmethylphenidate Hydrochloride, (d-MPH) in the Treatment of Fatigue in Sarcoidosis Subjects. | Sarcoidosis | Drug: d-methylphenidate | University of Cincinnati | Not recruiting | 18 Years | N/A | Both | 12 | Phase 4 | United States | |
| 97 | EUCTR2006-001816-56-DK | 11/05/2006 | 3 April 2017 | Can PET scan be used to assess disease activity in patients with sarcoidosis during treatment with adalimumab (Humira)? - KOMPLET | Can PET scan be used to assess disease activity in patients with sarcoidosis during treatment with adalimumab (Humira)? - KOMPLET | sarcoidosis | Trade Name: Humira Product Name: Humira Pharmaceutical Form: Injection* | Rigshospitalet | Authorised | Female: yes Male: yes | 10 | Phase 2 | Denmark | |||
| 98 | NCT00311246 | April 2006 | 19 February 2015 | Trial of Adalimumab in Progressive Sarcoidosis | A Prospective Open-Label Trial of Adalimumab in Progressive Sarcoidosis | Sarcoidosis | Drug: Adalimumab | University of Chicago | Abbott | Not recruiting | 18 Years | 85 Years | Both | 11 | Phase 2 | United States |
| 99 | NCT00279708 | January 2006 | 16 December 2017 | Atorvastatin to Treat Pulmonary Sarcoidosis | Atorvastatin as a Disease Modifying Agent in Stage II and III Pulmonary Sarcoidosis: A Randomized, Double-Blind, Placebo-Controlled Trial | Sarcoidosis, Pulmonary | Drug: Atorvastatin;Other: Placebo Oral Tablet | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | 18 Years | 70 Years | All | 55 | Phase 2 | United States | |
| 100 | NCT00402623 | January 2006 | 16 December 2017 | The Effect of Quercetin in Sarcoidosis | The Effect of Quercetin on the Increased Inflammatory and Decreased Antioxidant Status in Sarcoidosis | Sarcoidosis | Dietary Supplement: quercetin;Other: placebo | Maastricht University Medical Center | ZonMw: The Netherlands Organisation for Health Research and Development | Not recruiting | N/A | N/A | All | 18 | N/A | Netherlands |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 101 | NCT00305552 | February 2005 | 19 February 2015 | SARCOTHAL. Thalidomide in Skin Sarcoidosis | Randomized Controlled Trial of Thalidomide vs Placebo in Skin Sarcoidosis | Sarcoidosis | Drug: THALIDOMIDE | Assistance Publique - Hôpitaux de Paris | Not recruiting | 18 Years | N/A | Both | 40 | Phase 3 | France | |
| 102 | NCT00282438 | December 2003 | 16 December 2017 | Hematopoietic Stem Cell Support in Patients With Refractory Sarcoidosis | Hematopoietic Stem Cell Transplant in Patients With Refractory Sarcoidosis: A Phase I/II Trial | Sarcoidosis | Biological: Autologous hematopoietic stem cell transplantation;Biological: Allogeneic stem cell transplantation | Northwestern University | Not recruiting | 18 Years | 60 Years | All | 2 | Phase 1/Phase 2 | United States | |
| 103 | NCT00073437 | October 2003 | 19 February 2015 | A Study of Infliximab in Patients With Sarcoidosis | A Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Safety and Efficacy of Infliximab (Remicade?) in Subjects With Chronic Sarcoidosis With Pulmonary Involvement. | Sarcoidosis | Drug: Infliximab | Centocor, Inc. | Not recruiting | 18 Years | N/A | Both | 139 | Phase 3 | United States;Austria;Belgium;France;Germany;Netherlands;Sweden;Switzerland;United Kingdom;Italy | |
| 104 | NCT00262132 | September 2003 | 25 June 2018 | Mycophenolate for Pulmonary Sarcoidosis | Mycophenolate for Pulmonary Sarcoidosis | Pulmonary Sarcoidosis | Drug: Mycophenolate | Medical University of South Carolina | Hoffmann-La Roche | Not recruiting | 18 Years | N/A | All | 20 | Phase 3 | United States |
| 105 | NCT00001877 | February 1999 | 19 February 2015 | Treatment of Pulmonary Sarcoidosis With Pentoxifylline | Treatment of Pulmonary Sarcoidosis With Pentoxifylline | Pulmonary Sarcoidosis | Drug: Pentoxifylline | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | N/A | N/A | Both | 100 | Phase 2 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 106 | NCT00000596 | June 1978 | 19 February 2015 | Diffuse Fibrotic Lung Disease | Lung Diseases;Pulmonary Fibrosis;Sarcoidosis | Drug: prednisone;Drug: cyclophosphamide;Drug: dapsone | National Heart, Lung, and Blood Institute (NHLBI) | Not recruiting | 18 Years | N/A | Both | Phase 2 |